FIELD: biotechnology.
SUBSTANCE: invention relates to production of engineered botulinum toxins containing at least one amino acid modification, wherein said at least one amino acid modification increases isoelectric point (pI) of the engineered clostridial toxin to a value which is at least 0.2 pI units greater than pI in other respects identical unmodified botulinum toxin, and can be used in medicine.
EFFECT: obtained toxins can be effectively used in treating diseases in which therapy with botulinum toxin is indicated.
32 cl, 10 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT PROTEIN EXPRESSION IN DOUBLE-STRAND C FORM | 2006 |
|
RU2412253C2 |
| SORTASE-LABELED CLOSTRIDIA NEUROTOXINS | 2020 |
|
RU2801120C2 |
| GENETICALLY ENGINEERED CELLS SENSITIVE TO CLOSTRIDIAL NEUROTOXINS | 2020 |
|
RU2824389C2 |
| NEUROTOXINS THAT DISPLAY REDUCED BIOLOGICAL ACTIVITY | 2010 |
|
RU2582266C2 |
| NEUROTOXINS SHOWING SHORTENED BIOLOGICAL ACTIVITY | 2012 |
|
RU2646110C2 |
| THERAPEUTIC FUSION PROTEINS | 2012 |
|
RU2651492C2 |
| CELLULAR VAMP CLEAVAGE ASSAY | 2017 |
|
RU2807994C2 |
| METHOD OF PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDE | 2012 |
|
RU2673910C2 |
| METHODS OF INCREASING SPECIFIC PINCH OF BOTULINUM NEUROTOXIN BY CELLS | 2016 |
|
RU2684404C2 |
| DEGRADABLE CLOSTRIDIAL TOXINS | 2011 |
|
RU2561465C2 |
